



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/785,207	02/24/2004	Shanta Modak	070050.2534	8835
21003	7590	05/13/2010	EXAMINER	
BAKER BOTTS L.L.P.			SOROUSH, ALI	
30 ROCKEFELLER PLAZA				
44TH FLOOR				
NEW YORK, NY 10112-4498				
			ART UNIT	PAPER NUMBER
			1616	
			NOTIFICATION DATE	DELIVERY MODE
			05/13/2010	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

DLNYDOCKET@BAKERBOTTS.COM

Office Action Summary	Application No. 10/785,207	Applicant(s) MODAK ET AL.	
	Examiner ALI SOROUGH	Art Unit 1616	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 02 November 2009.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-5,7-10,12,16,19,20,22,33 and 35 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5,7-10,12,16,19,20,22,33 and 35 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>01282010</u> . | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Acknowledgement of Receipt

Applicant's response filed on 11/02/2009 to the Office Action mailed on 08/11/2009 is acknowledged.

Status of the Claims

Claims 6, 11, 13-15, 17, 18, 21, 23-32, and 34 are cancelled and claim 35 is newly added. Therefore, claims 1-5, 7-10, 12, 16, 19, 20, 22, 33, and 35 are currently pending examination for patentability.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

The provisional rejection of claims 1, 2, 3, 5, 7-10, 12, 16, 19, 20, and 22 on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3-11, and 17 of copending Application No. 10/622272 **is maintained**.

Response to Applicant's Arguments

Applicant argues that since the overlapping claims have not yet been patented Applicants will agree to submit a terminal disclaimer at such necessary time. Therefore, the instant rejection of claims 1, 2, 3, 5, 7-10, 12, 13, 16, 19, 20, and 22 on the ground of nonstatutory obviousness-type double patenting is maintained.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Applicant Claims
2. Determining the scope and contents of the prior art.
3. Ascertaining the differences between the prior art and the claims at issue; and resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Art Unit: 1616

1. The rejection of claims 1, 16, 19, and 22 under 35 U.S.C. 103(a) as being unpatentable over Broh-Kahn et al. (US Patent 3257276, Published 06/21/1966) in view of Burnier et al. (US Patent 5736574, Published 04/07/1998) as evidenced by Page (US Patent 4870108, Published 09/26/1989) **is maintained.**

Applicant Claims

Applicant claims a composition comprising alcohol, water, hydrogel, an emollient, octoxyglycerin and an antimicrobial.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

Broh-Kahn et al. teach an oral analgesic hydroalcoholic gel comprising: 8.72% choline salicylate, 0.01% cetyldimethylbenzylammonium chloride (benzalkonium chloride), 2.75% methyl cellulose (gelling agent), 5% glycerine (emollient), 39.16% ethyl alcohol, 0.143% oil of anise, 0.057% menthol, 0.2% cylcohexylsulfamic acid, and ~44% water. (See title and column 5, Lines 13-25). The gelling agent concentration ranges from 0.1 to 4% depending on the desired viscosity of the finished gel. (See column 4, Lines 60-73).

Page teaches that glycerin is an emollient. (See column 2, Line 36).

Ascertainment of the Difference Between Scope the Prior Art and the Claims (MPEP §2141.012)

Broh-Kahn et al. lacks a composition comprising octoxyglycerin. This deficiency is cured by the teachings of Burnier et al.

Art Unit: 1616

Burnier et al. teach combinatorial antimicrobial admixtures comprising at least one compound exhibiting antimicrobial activity and an antimicrobially synergistically effective amount of octoxyglycerin which are well suited for formulations in a wide variety of pharmaceutical and cosmetic compositions. (See abstract, Column 1, Lines 40-47, and Column 3, Lines 28-32). The antimicrobial action of this combination is advantageous since it is milder, while at the same time being at least as effective as that of the compounds of the prior art. (See column 1, Lines 48-50). The admixture preferably comprises 0.01 to 6% octoxyglycerin and 0.01 to 5% of the compound exhibiting antimicrobial activity. (See column 3, Lines 45-52).

***Finding of Prima Facie Obviousness Rational and Motivation
(MPEP §2142-2143)***

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to add the octoxyglycerin to the composition taught by Broh-Kahn et al., as suggested by Burnier et al., and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Burnier et al. teach that the addition of octoxyglycerin to an antimicrobial such as benzalkonium chloride will result in the advantageous combination of a milder antimicrobial.

In light of the foregoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

Art Unit: 1616

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Response to Applicant's Arguments

Applicant argues that the instant claims are not obvious over the teaching of Broh-Kan et al. in view of Burnier et al. because the Broh-Kahn et al. prefer a hydroalcoholic composition that has a viscosity of 4000 cps in contrast to Applicant's instantly claimed hydroalcoholic composition which has a viscosity of less than 2000 cps. Applicant's argument has been fully considered but found not to be persuasive. Broh-Khan et al. teach that the gelling agent can have concentrations of as little as 0.1 to as high as 4% depending on what the desired viscosity of the gel is to be. Therefore, it would have been obvious to one of ordinary skill in the art to adjust the concentration of methyl cellulose down in order to achieve the instantly claimed viscosity.

Applicant further argues that one of ordinary skill in the art would not be motivated to combine Burnier et al. with Broh-Kahn et al. since the first is directed to a topical antimicrobial composition and the latter is directed to an oral analgesic composition. Applicant's argument has been fully considered but found not to be persuasive. The composition of Broh-Kahn et al. is taught to be useful on the mucosa and oral cavity as well as on lip surfaces. (See column 1, Lines 9-14). Therefore, it is the Examiners position that the composition of Broh-Kahn et al. is a topical formulation.

Art Unit: 1616

Secondly, it is the Examiners position that the Broh-Kahn et al. is also an antimicrobial composition since it includes benzalkonium chloride. Therefore, it is the Examiners position that Broh-Kahn et al. and Burnier et al. are analogous art and one of ordinary skill in the art would have been motivated to combine the teachings as suggested.

Applicant also argues that there would be no reasonable expectation of success in modification of Broh-Kahn et al. by the addition of octoxyglycerin as taught by Burnier et al. Applicant's argument has been fully considered but found not to be persuasive. It is the Examiners position that teachings of Burnier et al. would have led one of ordinary skill in the art to add octoxyglycerin to the composition of Broh-Kahn et al. in order achieve a synergistically effective amount of antimicrobial.

2. The rejection of Claim 7 under 35 U.S.C. 103(a) as being unpatentable over Broh-Kahn et al. (US Patent 3257276, Published 06/21/1966) in view of Burnier et al. (US Patent 5736574, Published 04/07/1998) further in view of Noda et al. (US Patent 4393076, Published 07/12/1983) as evidenced by Page (US Patent 4870108, Published 09/26/1989) **is maintained.**

Applicant Claims

Applicant claims a composition comprising alcohol, water, hydroxyethylcellulose, an emollient, octoxyglycerin and an antimicrobial.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

The combined teachings of Brohn-Kahn et al. and Burnier et al. are discussed above.

***Ascertainment of the Difference Between Scope the Prior Art and the Claims
(MPEP §2141.012)***

Broh-Kahn et al. lacks a composition comprising hydroxyethylcellulose. This deficiency is cured by the teachings of Noda et al.

Noda et al. teach an anti-inflammatory and analgesic gel composition comprising a gelling agent selected from methylcellulose and hydroxyethylcellulose. (See column 14, claim 7).

***Finding of Prima Facie Obviousness Rational and Motivation
(MPEP §2142-2143)***

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to substitute methylcellulose for hydroxyethylcellulose in the composition taught by Broh-Kahn et al., as suggested by Noda et al., and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Noda et al. teach that these gelling agents are suitable alternatives for one another.

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of

Art Unit: 1616

ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Response to Applicant's Arguments

Applicant further argues that one of ordinary skill in the art would not be motivated to combine Burnier et al. and Broh-Kahn et al. since the first two are directed to topical compositions and the latter is directed to an oral composition. Applicant's argument has been fully considered but found not to be persuasive. The composition of Broh-Kahn et al. is taught to be useful on the mucosa and oral cavity as well as on lip surfaces. (See column 1, Lines 9-14). Therefore, it is the Examiners position that the composition of Broh-Kahn et al. is a topical formulation. Therefore, it is the Examiners position that Broh-Kahn et al. and Burnier et al. are analogous art and one of ordinary skill in the art would have been motivated to combine the teachings as suggested. Therefore, the rejection of claim 7 under 35 U.S.C. 103(a) is maintained.

3. The rejection of claims 2-5, 8, 9, 10, and 33 under 35 U.S.C. 103(a) as being unpatentable over Broh-Kahn et al. (US Patent 3257276, Published 06/21/1966) in view of Burnier et al. (US Patent 5736574, Published 04/07/1998) further in view of Modak et al. (US Patent 596510, Published 04/07/1998) as evidenced by Page (US Patent 4870108, Published 09/26/1989) **is maintained**.

Applicant Claims

Art Unit: 1616

Applicant claims a composition comprising alcohol, water, hydroxyethylcellulose, an emollient, octoxyglycerin and an antimicrobial. Further comprising other suitable components such as emulsifiers, thickening agents, and silicone polymers.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

The combined teachings of Brohn-Kahn et al. and Burnier et al. are discussed above.

Ascertainment of the Difference Between Scope the Prior Art and the Claims (MPEP §2141.012)

Broh-Kahn et al. lacks a composition comprising emulsifiers, thickening agents, and silicone polymers. This deficiency is cured by the teachings of Modak et al.

Modak et al. teaches a topical composition comprising a gel formed between zinc gluconate and solvent selected from the group consisting of water and alcohol and mixtures thereof, and further comprising a thickening agent, a hydrophobic polymer, an emulsifying agent, an emollient, and an antioxidant. The thickening agent is selected from a stearyl alcohol and cationic hydroxyethyl cellulose; the hydrophobic polymer is selected from dimethicone, petroleum and byproducts thereof; the emulsifying agent is selected from PEG-14M and Incroquet Behenzyl TMS. The zinc gluconate is useful as an anti-irritant effect on the skin. The composition can further include antimicrobials. (See abstract, column 26, Lines 14-67 and column 27, Lines 1-14).

Finding of Prima Facie Obviousness Rational and Motivation (MPEP §2142-2143)

Art Unit: 1616

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to add emulsifiers, thickening agents, and silicone polymers the composition taught by Broh-Kahn et al., as suggested by Modak et al., and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Modak et al. teach that such components are common adjuvants added to hydroalcoholic gels.

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Response to Applicant's Arguments

Applicant argues that the deficiencies of Broh-Kahn et al. and Burnier et al. are not cured by the teachings of Modak et al. Applicant's argument has been fully considered but found not to be persuasive. The Examiner has already addressed all of Applicant's arguments with regard to the perceived deficiencies. Therefore, the rejection of claims 2-5, 8, 9, 10, and 33 under 35 U.S.C. 103(a) is maintained.

New Grounds of Rejection

Art Unit: 1616

4. Claim 35 is rejected under 35 U.S.C. 103(a) as being unpatentable over Broh-Kahn et al. (US Patent 3257276, Published 06/21/1966) in view of Burnier et al. (US Patent 5736574, Published 04/07/1998) further in view of fei et al. (US Patent 6485716 B1, Published 11/26/2002, Filed 10/05/2001) as evidenced by Page (US Patent 4870108, Published 09/26/1989).

Applicant Claims

Applicant claims a composition comprising alcohol, water, hydroxyethylcellulose, an emollient, octoxyglycerin and an antimicrobial.

Determination of the Scope and Content of the Prior Art (MPEP §2141.01)

The combined teachings of Brohn-Kahn et al. and Burnier et al. are discussed above.

Ascertainment of the Difference Between Scope the Prior Art and the Claims (MPEP §2141.012)

Broh-Kahn et al. lacks a composition wherein the emollient is PPG-3 myristyl ether. This deficiency is cured by the teachings of Noda et al.

Feil et al. teach clear, elastomer, gel compositions. (See abstract). The composition can comprise an emollient preferably selected from a group consisting of PPG-3 myristyl ether. (See column 11, Lines 34-55).

Finding of Prima Facie Obviousness Rational and Motivation (MPEP §2142-2143)

Art Unit: 1616

It would have been obvious to one of ordinary skill in the art at the time the claimed invention was made to substitute PPG-3 myristyl ether for glycerin in the composition taught by Broh-Kahn et al., as suggested by Fei et al., and produce the instant invention.

One of ordinary skill in the art would have been motivated to do this because Fei et al. teach that these emollients are suitable alternatives for one another.

In light of the forgoing discussion, the Examiner concludes that the subject matter defined by the instant claims would have been obvious within the meaning of 35 USC 103(a).

From the teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was *prima facie* obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

Art Unit: 1616

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ali Soroush whose telephone number is (571) 272-9925. The examiner can normally be reached on Monday through Thursday 8:30am to 5:00pm E.S.T.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's Supervisor, Johann Richter can be reached on (571) 272-0646. The fax phone number For the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call

Application/Control Number: 10/785,207

Page 15

Art Unit: 1616

800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Ali Soroush
Patent Examiner
Art Unit: 1616

/Johann R. Richter/
Supervisory Patent Examiner, Art Unit 1616